Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Myrbetriq | Mirabegron | Overactive bladder | List with criteria/condition | Complete | ||
| Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | ||
| Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | ||
| Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | ||
| Tivicay | Dolutegravir | HIV infection | List | Complete | ||
| Stivarga (GIST) | Regorafenib | Gastrointestinal Stromal Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn |
Last Updated : May 19, 2024